What Actually Happens When a Peptide Order Is Stopped at the Border

Start with the hierarchy, because most confusion lives here

Nearly every online claim about peptide importing conflates four very different kinds of document. Only the first two are law.

The manual disclaims its own force in terms that leave little room:

The personal importation policy, in its own words

This is the passage the “personal use exemption” is built on. Read the last sentence.

And then the sentence that decides most peptide cases:

The three-month supply is not a standalone allowance

The often-quoted “3 month supply” sits inside one prong of a conjunctive test that also requires the product to address a serious condition with no domestic treatment available, and requires that there be no known commercialisation or promotion to U.S. residents by those distributing it. A vendor with a US-facing website marketing to US buyers fails that element outright — and that same marketing is what triggers alerts 66-41 and 66-57 in the first place. The quantity also cuts the other way: FDA may treat a shipment as commercial where the supply exceeds roughly three months.

What happens, step by step

1. CBP sets the parcel aside. At an International Mail Facility, a CBP officer examines parcels and holds anything that appears to contain a drug. CBP administers the border; FDA decides whether the article complies with the acts it enforces.
2. FDA reviews. A documentary sample — labels, inserts, the vendor's paperwork — is usually enough. No laboratory analysis is required to refuse.
3. Notice of FDA Action — Detained. For drugs the designation is “DETAINED — Subject to Refusal and Administrative Destruction.” This satisfies the notice requirement in § 381(a).
4. You get 10 working days. Testimony may be submitted informally. In practice, the only winning arguments are that the article is not what FDA thinks it is, or that it qualifies for a labelling exemption — not that it is for personal use.
5. Refusal. Under § 381(a) the trigger is deliberately low: refusal follows if it merely “appears” the article is adulterated, misbranded, or in violation of § 355.
6. Destruction, not return. Where the article is a drug valued at $2,500 or less, it is destroyed without any opportunity to export.

FDA refusal is not the same as CBP seizure

One nuance worth knowing. Section 1595a(c)(2)(A) is discretionary — goods restricted on health or safety grounds may be seized. But § 1595a(c)(1) is mandatory for merchandise that is “stolen, smuggled, or clandestinely imported.” Misdeclaring a shipment to get it through — the “stealth shipping” that some vendors advertise — is what moves a parcel from the discretionary track to the mandatory one.

The GLP-1 “Green List” inverts the usual presumption

Import Alert 66-80, launched in September 2025, is the first import alert built around a peptide drug class. Its structure is the reverse of a normal alert: rather than detaining listed bad actors, it detains everything except manufacturers affirmatively cleared onto a Green List. It names semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, orforglipron and retatrutide among others. FDA described evaluating foreign GLP-1 API sites and finding a substantial share non-compliant, with a pattern of firms registering, offering product, refusing records requests, then deregistering.

Section 804 is not the loophole it is described as

21 U.S.C. § 384 is frequently cited as authorising personal importation from Canada. It does not operate today. The 2020 Secretarial certification covered the state importation pathway but expressly excluded § 804(j), stating that the personal importation provisions “are not being implemented” and that any implementation would require a separate certification. None has been made.

Even fully implemented, § 804(j)(3) would require an FDA-approved drug in finished dosage form, from a licensed Canadian pharmacy, on a valid prescription. Research peptides and bulk API from China fall entirely outside it.

Enforcement is real, and it reaches vendors hardest

• A single week-long joint CBP/FDA operation in Cincinnati seized 63 shipments of counterfeit and unapproved drugs worth over $268,000, including counterfeit GLP-1 pens, arriving from China, South Korea, India, Italy, Guatemala, the UK and Canada.
• FDA reported destroying more than 12.9 million units — over 41 tons — in the years following the 2016 rollout of administrative destruction across nine mail facilities.
• Vendors importing peptides from China now draw prison sentences, not just letters. See our piece on why “research use only” makes those cases worse.

The short version

• Importing an unapproved new drug violates §§ 331(d) and 355(a) whether or not it is for personal use. Importation is interstate commerce.
• The personal importation policy is discretion, not a right, and generally does not apply to goods under an import alert.
• Refusal follows if the article merely appears violative — a low bar, met by documentary review alone.
• Under $2,500, expect destruction with no export option and no refund.
• Section 384 offers no route; § 804(j) has never been implemented.